What’s going on in the world of vasculitis…?
Prague 14-15 Nov 2025.
Once a year, patient representatives from across Europe gather for the European Vasculitis Patient Summit.This special meeting offers a unique platform to exchange experiences, share knowledge, and discuss current vasculitis topics.
French EGPA patients and their doctors received disappointing news recently when the French health authority (HAS) decided not to reimburse Fasenra (benralizumab) for treating EGPA. This decision has created significant concern within the EGPA community, as it limits access to what could be an important alternative treatment option.
On September 18th, 2025, leading EGPA specialists from across Europe gathered in Paris for the 10th meeting of the European EGPA Study Group. The research-focused conference, held at the historic Maison de l’Amérique Latine, brought together doctors and researchers to present and discuss the latest scientific developments in understanding and treating this rare autoimmune condition. A small number of patient representatives also attended this primarily medical meeting.
An additional analysis from the MANDARA study shows that steroid-free remission is possible for a subset of patients with EGPA. Biologic therapies such as benralizumab and mepolizumab can support this goal, with benralizumab showing somewhat better outcomes in this specific context.
In a recent article in Rheumatology (Oxford) the Canadian vasculitis experts Christian Pagnoux and Arielle Mendel reflected on the launch of the new BSR Guidelines for the management of AAV.
The authors are welcoming the new 2025 British Society for Rheumatology (BSR) guidelines while emphasizing why doctors should read ALL available guidelines, not just one.
Real world experience A recently published study in Clinical and Experimental Rheumatology offers new real-world data from the University of